The Readout Loud

View Top 200 Chart

Back to Rankings Page

Business
**The Readout Loud**

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Latest Episodes:

Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping Sep 13, 2018

Show notes

Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Episode 27: Live from Boston! Sep 06, 2018

Show notes

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer Aug 30, 2018

Show notes

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags Aug 23, 2018

Show notes

Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T Aug 16, 2018

Show notes

How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?

Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers Aug 09, 2018

Show notes

Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?

Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest Aug 02, 2018

Show notes

What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.

Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data Jul 26, 2018

Show notes

What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?

Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season Jul 19, 2018

Show notes

Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.

Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines' Jul 12, 2018

Show notes

Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected